[go: up one dir, main page]

DE60328198D1 - Verfahren zur Vorhersage des Behandlungserfolgs mit Rivastigmine basierend auf einer Bestimmung des ApoE Genotyps eines Demenzkranken - Google Patents

Verfahren zur Vorhersage des Behandlungserfolgs mit Rivastigmine basierend auf einer Bestimmung des ApoE Genotyps eines Demenzkranken

Info

Publication number
DE60328198D1
DE60328198D1 DE60328198T DE60328198T DE60328198D1 DE 60328198 D1 DE60328198 D1 DE 60328198D1 DE 60328198 T DE60328198 T DE 60328198T DE 60328198 T DE60328198 T DE 60328198T DE 60328198 D1 DE60328198 D1 DE 60328198D1
Authority
DE
Germany
Prior art keywords
rivastigmine
determination
treatment success
dementia patient
apoe genotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60328198T
Other languages
English (en)
Inventor
Roger Michael Lane
Mihael Hristos Polymeropoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60328198D1 publication Critical patent/DE60328198D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
DE60328198T 2002-08-07 2003-08-06 Verfahren zur Vorhersage des Behandlungserfolgs mit Rivastigmine basierend auf einer Bestimmung des ApoE Genotyps eines Demenzkranken Expired - Lifetime DE60328198D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40169402P 2002-08-07 2002-08-07
PCT/EP2003/008719 WO2004015140A1 (en) 2002-08-07 2003-08-06 Methods for the treatment of dementia based on apo e genotype

Publications (1)

Publication Number Publication Date
DE60328198D1 true DE60328198D1 (de) 2009-08-13

Family

ID=31715721

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60328198T Expired - Lifetime DE60328198D1 (de) 2002-08-07 2003-08-06 Verfahren zur Vorhersage des Behandlungserfolgs mit Rivastigmine basierend auf einer Bestimmung des ApoE Genotyps eines Demenzkranken

Country Status (14)

Country Link
US (3) US20060160079A1 (de)
EP (1) EP1529116B1 (de)
JP (1) JP2005534710A (de)
CN (1) CN1681941A (de)
AT (1) ATE435302T1 (de)
AU (1) AU2003266967B2 (de)
BR (1) BR0313588A (de)
CA (1) CA2494585A1 (de)
DE (1) DE60328198D1 (de)
DK (1) DK1529116T3 (de)
ES (1) ES2327914T3 (de)
IL (1) IL166466A0 (de)
PT (1) PT1529116E (de)
WO (1) WO2004015140A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
WO2006014755A2 (en) * 2004-07-20 2006-02-09 Wyeth Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer’s disease
US20060228728A1 (en) * 2005-01-31 2006-10-12 Perlegen Sciences, Inc. Genetic basis of Alzheimer's disease and diagnosis and treatment thereof
US7740593B2 (en) 2005-12-09 2010-06-22 Senorx, Inc Guide block for biopsy or surgical devices
EP2650379B1 (de) 2007-07-31 2015-09-16 Accera, Inc. Verwendung genomischer und ketogener Verbindungen zur Behandlung von beeinträchtigten kognitiven Funktionen
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CA2729622C (en) 2008-07-03 2017-07-25 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
AU2018239433B2 (en) 2017-03-21 2024-02-01 Indiana University Research And Technology Corporation A genetically modified mouse expressing human APOE4p and mouse Trem2 p.R47H and methods of use thereof
EP3630098B1 (de) * 2017-05-24 2021-03-24 H. Lundbeck A/S Kombination eines 5-ht6-rezeptorantagonisten und eines acetylcholinesterase-hemmers zur verwendung bei der behandlung von morbus alzheimer bei patienten mit apoe4-allelen
WO2019246483A1 (en) * 2018-06-21 2019-12-26 The Jackson Laboratory Genetically modified mouse models of alzheimer's disease
WO2020176846A2 (en) * 2019-02-28 2020-09-03 The Rockefeller University Apoe genotyping in cancer prognostics and treatment
HUE067466T2 (hu) 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk
CN117886933A (zh) * 2023-12-28 2024-04-16 上海良润生物医药科技有限公司 一种载脂蛋白e检测试剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009155A1 (en) * 1992-10-13 1994-04-28 Duke University Methods of detecting alzheimer's disease
CA2111503A1 (en) * 1993-12-15 1995-06-16 Mcgill University Apolipoprotein e polymorphism and alzheimer's disease
FR2765591B1 (fr) * 1997-07-01 2002-08-09 Pasteur Institut Procede de diagnostic de la maladie d'alzheimer
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
JP2000069963A (ja) * 1998-08-31 2000-03-07 Igaku Seibutsugaku Kenkyusho:Kk アポリポプロテインｅ４特異モノクローナル抗体
PL196945B1 (pl) * 1998-10-01 2008-02-29 Novartis Ag Doustna kompozycja farmaceutyczna o kontrolowanym uwalnianiu zawierająca rywastygminę oraz jej zastosowanie
MXPA02012560A (es) * 2000-06-30 2003-05-14 Elan Pharm Inc Compuestos para tratar la enfermedad de alzheimer.

Also Published As

Publication number Publication date
IL166466A0 (en) 2006-01-15
EP1529116B1 (de) 2009-07-01
WO2004015140A1 (en) 2004-02-19
AU2003266967B2 (en) 2006-11-16
US20060160079A1 (en) 2006-07-20
EP1529116A1 (de) 2005-05-11
AU2003266967A1 (en) 2004-02-25
CN1681941A (zh) 2005-10-12
BR0313588A (pt) 2005-07-12
ATE435302T1 (de) 2009-07-15
ES2327914T3 (es) 2009-11-05
US20100240744A1 (en) 2010-09-23
DK1529116T3 (da) 2009-11-09
CA2494585A1 (en) 2004-02-19
PT1529116E (pt) 2009-09-10
US20080214662A1 (en) 2008-09-04
JP2005534710A (ja) 2005-11-17

Similar Documents

Publication Publication Date Title
DE60328198D1 (de) Verfahren zur Vorhersage des Behandlungserfolgs mit Rivastigmine basierend auf einer Bestimmung des ApoE Genotyps eines Demenzkranken
ATE488251T1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
EP1788938A4 (de) System, software und verfahren zur detektion von schlafgestörter atmung mithilfe eines elektrokardiogramms
PE20120015A1 (es) Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
DE60325617D1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
HUP0302332A2 (hu) Génkimutatási eljárás ErbB-antagonistával végzett rákterápiára adott hatékony reakció valószínûségének növelésére
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
ATE426043T1 (de) Verfahren zur identifizierung des brustkrebsrisikos
ATE511645T1 (de) Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme
ATE519503T1 (de) Verfahren zur behandlung von patienten mit hepatitis c
ATE503563T1 (de) Blockverhältnisverbesserendes mittel für permeable membran, verfahren zur blockverhältnisverbesserung, permebale membran und wasserbehandlungsverfahren
ATE469245T1 (de) Auf genetischem targeting basierendes verfahren zur behandlung mit bucindolol
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
TW200731984A (en) C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor H
DE602005023363D1 (de) Vorrichtung und Verfahren zur Authentifizierung von Blutgefässen
DE602005020113D1 (de) Verfahren zur behandlung von akuten rhinosinusitis
WO2007006862A3 (en) Method and kit for detecting a risk of coronary heart disease
ATE487947T1 (de) Verfahren zur diagnose und behandlung auf nr2- peptiden beruhender zerebrovaskulärer ereignisse
WO2007013360A3 (en) Pancreatic cancer related gene cst6 and gabrp
ATE546548T1 (de) Verfahren zur prognose des nutzens einer antioxidationshemmenden therapie zur vorbeugung von herz-kreislauf-erkrankungen bei hyperglykämischen patienten
ATE543429T1 (de) Verfahren zur bestimmung des sympathikus-tonus und messsystem dafür
DE602005016697D1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
WO2005118834A3 (en) Methods for identifying risk of breast cancer and treatment thereof
DE60319719D1 (de) Verfahren zur voraussage der erhöhung von cholesterin während einer immunosuppresiven therapie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition